Shawn Marshall Rose

Insider

First SEC filing: June 25, 2025 · Latest: June 25, 2025

On this page

Insider at

0 buys (P) 0 sells (S) Net: $0 + 3 non-open-market transactions below last 12 months, based on the transactions shown below

Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted

No open-market trades on record; showing all filings.

Date	Ticker	Code	Shares	Price	Value	Owned after	Δ own	A/D	vs now
Jan. 6, 2026	NKTX	A	139,000	—	—	139,000 Direct	—	Acquired	(price as of 2026-08-20)
Jan. 6, 2026	NKTX	A	70,000	—	—	70,000 Direct	—	Acquired	(price as of 2026-08-20)
June 23, 2025	NKTX	A	500,000	—	—	500,000 Direct	—	Acquired	(price as of 2026-08-20)

P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding

Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.

Options, RSUs and convertible securities reported on Form 4 Table II.

Date	Ticker	Security	Underlying	Exercise price	Expiration	Shares	A/D
Jan. 6, 2026	NKTX	Stock Option (right to buy)	Common Stock (139,000)	$1.93	Jan. 5, 2036	139,000	Acquired
June 23, 2025	NKTX	Stock Option (right to buy)	Common Stock (500,000)	$1.75	June 22, 2035	500,000	Acquired

Exercise/conversion price is blank when not applicable (e.g. RSUs).

Matched by name from proxy statements (DEF 14A) — verify against the filing.

M.D., Ph.D.(2)Chief Medical Officer and Head of Research and Development

Fiscal year	Salary	Bonus	Stock awards	Option awards	Non-equity incentive	Pension change	Other	Total
2025	$316,591	—	—	$709,300	$189,720	—	$9,162	$1,224,773

Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.